Results 1 to 10 of about 7,936 (162)

Effect of tiotropium inhaler use on mortality in patients with tuberculous destroyed lung: based on linkage between hospital and nationwide health insurance claims data in South Korea [PDF]

Respiratory Research, 2019
Background Although bronchodilator inhaler therapy can improve lung function in patients with tuberculous destroyed lung (TDL), its effect on mortality has not been studied.
Ho Cheol Kim, Tae Hoon Kim, Ye-Jee Kim, Chin Kook Rhee, Yeon-Mok Oh   +4 more
doaj   +2 more sources

Effect of 12 weeks of once-daily tiotropium/olodaterol on exercise endurance during constant work-rate cycling and endurance shuttle walking in chronic obstructive pulmonary disease [PDF]

Therapeutic Advances in Respiratory Disease, 2018
Background: The TORRACTO ® study evaluated the effects of tiotropium/olodaterol versus placebo on endurance time during constant work-rate cycling and constant speed shuttle walking in patients with chronic obstructive pulmonary disease (COPD) after 12 ...
François Maltais, Denis O’Donnell, Juan Bautista Gáldiz Iturri, Anne-Marie Kirsten, Dave Singh, Alan Hamilton, Kay Tetzlaff, Yihua Zhao, Richard Casaburi   +8 more
doaj   +2 more sources

Lung function and long-term safety of tiotropium/olodaterol in East Asian patients with chronic obstructive pulmonary disease

International Journal of COPD, 2017
Chunxue Bai,1 Masakazu Ichinose,2 Sang Haak Lee,3 Kwan Ho Lee,4 Olaf Jöns,5 Ulrich Bothner,6 Yihua Zhao,7 Roland Buhl8 1Department of Pulmonary Medicine, Shanghai Respiratory Research Institute, Zhongshan Hospital, Fudan University, Shanghai, China;
Bai C, Ichinose M, Lee SH, Lee KH, Jöns O, Bothner U, Zhao Y, Buhl R   +7 more
doaj   +1 more source

Anti-inflammatory effects of tiotropium in COPD: a randomised double-blind trial [PDF]

ERJ Open Research
Background COPD is a major global health issue characterised by respiratory symptoms and exacerbations, significantly impacting mortality and quality of life.
Lisa H. van Smoorenburg, Tatiana Karp, Benedikt Ditz, Wouter H. van Geffen, Victor Guryev, Ali Almusa, Loes Kistemaker, Reinoud Gosens, Maarten van den Berge, Huib A.M. Kerstjens   +9 more
doaj   +2 more sources

Comparative In Vitro Deposition Analysis of Formoterol, Glycopyrronium, and Tiotropium Delivered via Capsule-Based DPI. [PDF]

Pharmaceutics
Sikora A, Chałupka J, Lewandowska K, Drapińska P, Marszałł MP.   +4 more
europepmc   +3 more sources

UK-specific cost-effectiveness of tiotropium + olodaterol fixed-dose combination versus other LAMA + LABA combinations in patients with COPD

ClinicoEconomics and Outcomes Research, 2016
Abigail Tebboth,1 Andrew Ternouth,1 Nuria Gonzalez-Rojas2 1Boehringer Ingelheim Ltd., Bracknell, UK; 2Boehringer Ingelheim GmBH, Ingelheim, Germany Objective: The aim of this study is to assess the cost-effectiveness of other long-acting muscarinic ...
Tebboth A, Ternouth A, Gonzalez-Rojas N
doaj   +3 more sources

Clinical predictors of treatment response to tiotropium add-on therapy in adult asthmatic patients: From multicenter real-world cohort data in Korea

World Allergy Organization Journal, 2022
Background: Tiotropium, a long-acting muscarinic antagonist, is recommended for add-on therapy to inhaled corticosteroids (ICS)-long-acting beta 2 agonists (LABA) for severe asthma.
Ji-Su Shim, MD, PhD, Juhae Jin, MA, Sae-Hoon Kim, MD, PhD, Taehoon Lee, MD, PhD, An-Soo Jang, MD, PhD, Chan Sun Park, MD, PhD, Jae-Woo Jung, MD, PhD, Jae-Woo Kwon, MD, PhD, Ji-Yong Moon, MD, PhD, Min-Suk Yang, MD, PhD, Jaechun Lee, MD, PhD, Jeong-Hee Choi, MD, PhD, Yoo Seob Shin, MD, PhD, Hee-Kyoo Kim, MD, PhD, Sujeong Kim, MD, PhD, Joo-Hee Kim, MD, PhD, Sang-Heon Cho, MD, PhD, Young-Hee Nam, MD, PhD, Sang-Hoon Kim, MD, PhD, So Young Park, MD, PhD, Gyu Young Hur, MD, PhD, Sang-Ha Kim, MD, PhD, Hye-Kyung Park, MD, PhD, Hyun Jung Jin, MD, PhD, Jae-Hyun Lee, MD, PhD, Jung-Won Park, MD, PhD, Ho Joo Yoon, MD, PhD, Byoung Whui Choi, MD, PhD, Young-Joo Cho, MD, PhD, Min-Hye Kim, MD, PhD, Tae-Bum Kim, MD, PhD   +30 more
doaj   +1 more source

Cost-effectiveness of the fixed-dose combination tiotropium/olodaterol versus tiotropium monotherapy or a fixed-dose combination of long-acting β2-agonist/inhaled corticosteroid for COPD in Finland, Sweden and the Netherlands: a model-based study

BMJ Open, 2021
Objectives Chronic obstructive pulmonary disease (COPD) guidelines advocate treatment with combinations of long-acting bronchodilators for patients with COPD who have persistent symptoms or continue to have exacerbations while using a single ...
Maureen Rutten-van Mölken, Martine Hoogendoorn, Isaac Corro Ramos, Stéphane Soulard, Jennifer Cook, Erkki Soini, Emma Paulsson   +6 more
doaj   +1 more source

Long-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy over 52 Weeks in Patients with Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Study. [PDF]

PLoS ONE, 2015
This study assessed the long-term safety and efficacy of tiotropium Respimat, a long-acting inhaled anticholinergic bronchodilator, in asthma, added on to inhaled corticosteroids (ICS) with or without long-acting β2-agonist (LABA).285 patients with ...
Ken Ohta, Masakazu Ichinose, Yuji Tohda, Michael Engel, Petra Moroni-Zentgraf, Satoko Kunimitsu, Wataru Sakamoto, Mitsuru Adachi   +7 more
doaj   +1 more source

Effect of different doses of Budesonide combined with Tiotropium bromide inhalation on elderly patients with chronic obstructive pulmonary disease. [PDF]

Pak J Med Sci
Yu J, Ni J, Chen X, Fang Y, Fu S.
europepmc   +3 more sources